Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Aultman Health Foundation — Canton, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Dayton Children's Hospital — Dayton, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Ohio: - University of Cincinnati Cancer Institute — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- The Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Ohio: - Children's Hospital Medical Center of Akron — Akron, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Rainbow Babies and Childrens Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Ohio: - Nationwide Children's Hospital — Columbus, Ohio
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- Toledo Clinic Cancer Center — Toledo, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Ohio: - Local Institution - 2112 — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Ohio: - Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: Patrick Wen, MD
NCT ID: NCT02977780
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Ohio: - Cincinnati Children's Hospital — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Industry
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study…
Sponsor: Alpheus Medical, Inc.
NCT ID: NCT07225621
Sites in Ohio: - Ohio State University — Columbus, Ohio
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Academic/Other
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05843253
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will …
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05278208
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
Phase 2 Recruiting Academic/Other
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein,…
Sponsor: The University of Texas Health Science Center at San Antonio
NCT ID: NCT04559230
Sites in Ohio: - Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine th…
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT01891318
Sites in Ohio: - University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT04923542
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-0…
Sponsor: Trogenix ltd
NCT ID: NCT07346144
Sites in Ohio: - Ohio State University Hospital — Columbus, Ohio
Phase 2 Recruiting Academic/Other
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, …
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT07248228
Sites in Ohio: - University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio